| Dose-response |
Short-term (1-30 days) |
C57BL/6 mice (PFOS): Male C57BL/6 (H-2b)mice (6–8 weeks old at the beginning of each experiment) were obtained either from the Center for Microbiology and TumorBiology at Karolinska Institute (Stockholm, Sweden) or from M&B (Ry, Denmark). PPAR-null male 129/Sv mice (originally obtained from Dr. F.J. Gonzalez, National Cancer Institute, National Institutes of Health, Bethesda, MD) (Lee et al., 1995) and their wild-type littermates were a kind gift from Professor G. Dallner to our department. All animals were kept at the animal facilities of the Wenner-Gren Institute, Stockholm University, with a 12-h dark/12-h light cycle and access to tap water and diet ad libitum. The firstmouse strain was chosen because of its wide use and paradigmatic status in immunological research (Peters et al., 2007), and the second strain was chosen because of the availability of appropriate transgenic animals. These experiments were pre-approved by the Northern Stockholm Ethical Committee for Animal Experimentation (N380/03, N299/05 and N300/05). |
| wildtype littermates |
Short-term (1-30 days) |
wildtype littermates (PFOS): Male C57BL/6 (H-2b)mice (6–8 weeks old at the beginning of each experiment) were obtained either from the Center for Microbiology and TumorBiology at Karolinska Institute (Stockholm, Sweden) or from M&B (Ry, Denmark). PPAR-null male 129/Sv mice (originally obtained from Dr. F.J. Gonzalez, National Cancer Institute, National Institutes of Health, Bethesda, MD) (Lee et al., 1995) and their wild-type littermates were a kind gift from Professor G. Dallner to our department. All animals were kept at the animal facilities of the Wenner-Gren Institute, Stockholm University, with a 12-h dark/12-h light cycle and access to tap water and diet ad libitum. The firstmouse strain was chosen because of its wide use and paradigmatic status in immunological research (Peters et al., 2007), and the second strain was chosen because of the availability of appropriate transgenic animals. These experiments were pre-approved by the Northern Stockholm Ethical Committee for Animal Experimentation (N380/03, N299/05 and N300/05). |
| 129/Sv PPARalpha-null mice |
Short-term (1-30 days) |
129/Sv PPARalpha-null mice (PFOS): Male C57BL/6 (H-2b)mice (6–8 weeks old at the beginning of each experiment) were obtained either from the Center for Microbiology and TumorBiology at Karolinska Institute (Stockholm, Sweden) or from M&B (Ry, Denmark). PPAR-null male 129/Sv mice (originally obtained from Dr. F.J. Gonzalez, National Cancer Institute, National Institutes of Health, Bethesda, MD) (Lee et al., 1995) and their wild-type littermates were a kind gift from Professor G. Dallner to our department. All animals were kept at the animal facilities of the Wenner-Gren Institute, Stockholm University, with a 12-h dark/12-h light cycle and access to tap water and diet ad libitum. The firstmouse strain was chosen because of its wide use and paradigmatic status in immunological research (Peters et al., 2007), and the second strain was chosen because of the availability of appropriate transgenic animals. These experiments were pre-approved by the Northern Stockholm Ethical Committee for Animal Experimentation (N380/03, N299/05 and N300/05). |
| Single dose-level |
Short-term (1-30 days) |
C57BL/6 mice (PFOA): Male C57BL/6 (H-2b)mice (6–8 weeks old at the beginning of each experiment) were obtained either from the Center for Microbiology and TumorBiology at Karolinska Institute (Stockholm, Sweden) or from M&B (Ry, Denmark). PPAR-null male 129/Sv mice (originally obtained from Dr. F.J. Gonzalez, National Cancer Institute, National Institutes of Health, Bethesda, MD) (Lee et al., 1995) and their wild-type littermates were a kind gift from Professor G. Dallner to our department. All animals were kept at the animal facilities of the Wenner-Gren Institute, Stockholm University, with a 12-h dark/12-h light cycle and access to tap water and diet ad libitum. The firstmouse strain was chosen because of its wide use and paradigmatic status in immunological research (Peters et al., 2007), and the second strain was chosen because of the availability of appropriate transgenic animals. These experiments were pre-approved by the Northern Stockholm Ethical Committee for Animal Experimentation (N380/03, N299/05 and N300/05). |